Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117378 | 0.85 | CTSB (0.50) | TDP1CTSBALDH1A1ARPLAU | |
| SCHEMBL27066 | 0.81 | CYP3A4 (0.50) | TDP1ALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL29405309 | 0.81 | CYP3A4 (0.50) | TDP1ALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL14048632 | 0.80 | TDP1 (0.57) | TDP1CTSBALDH1A1ARPLAU | |
| SCHEMBL7788656 | 0.79 | TDP1 (0.80) | TDP1CTSBALDH1A1ARHPRT1 | |
| SCHEMBL187375 | 0.78 | PLAU (0.59) | TDP1ALDH1A1PLAUCYP3A4HSD17B10 | |
| SCHEMBL30135431 | 0.78 | PLAU (0.59) | TDP1ALDH1A1PLAUCYP3A4HSD17B10 | |
| SCHEMBL11466165 | 0.77 | TDP1 (0.57) | TDP1CTSBALDH1A1ARPLAU | |
| SCHEMBL30034632 | 0.76 | TDP1 (0.49) | TDP1ALDH1A1PLAUCYP3A4ALOX15 | |
| SCHEMBL11382980 | 0.75 | CYP3A4 (0.45) | TDP1ALDH1A1CYP3A4ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7432267-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMAPNY (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1414795-A4 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-6992102-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-22 | — | — | US | disclosed |
| EP-1463728-A4 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050256048-A1 | Selective androgen receptor modulators and methods for their identification, design and use | SALVATI MARK E | 2005-11-17 | — | — | US | disclosed |
| US-6960474-B2 | Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| CN-1443187-A | Fused ring modulators of nuclear hormone receptor function | BRISTOL MYERS SQUIBB CO (US) | 2003-09-17 | — | — | CN | disclosed |
| WO-2003053354-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | disclosed |
| EP-1299385-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1299094-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR IDENTIFICATION, DESIGN AND USE | Bristol-Myers Squibb Company (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-20 | — | — | US | disclosed |
| WO-2003011824-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020173445-A1 | Selective androgen receptor modulators and methods for their identification, design and use | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002000617-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR IDENTIFICATION, DESIGN AND USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000653-A2 | FUSED CYCLIC COMPOUNDS AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256048-A1 | Selective androgen receptor modulators and methods for their identification, design and use | AR, FSHR, LHCGR | TDP1 4422/4885CTSB 3810/4885ALDH1A1 2914/4885 |
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | NR2C2, NR0B2, NR0B1 | TDP1 4841/4885CTSB 4693/4885ALDH1A1 4495/4885 |
| US-20020173445-A1 | Selective androgen receptor modulators and methods for their identification, design and use | AR, FSHR, LHCGR | TDP1 4422/4885CTSB 3810/4885ALDH1A1 2914/4885 |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | TDP1 3077/4885CTSB 4450/4885ALDH1A1 763/4885 |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | TDP1 3841/4885CTSB 4427/4885ALDH1A1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.